Clinical Trial · NCT06148207

[18F]BF3-BPA Injection for PET Imaging Study of Gliomas in the Brain

Overview

In this clinical study, we proposed to perform \[18F\]BF3-BPA PET imaging in subjects with gliomas, to observe the binding ability and non-specific binding of the tracer to glioma lesions in vivo, and at the same time to evaluate the effectiveness of \[18F\]BF3-BPA in the diagnosis and differential diagnosis of glioma, and to evaluate the tolerability and safety of the tracer and the imaging method. The efficacy of \[18F\]BF3-BPA in the diagnosis and differential diagnosis of gliomas will be evaluated, as well as the tolerability and safety of this tracer and imaging method. This study will provide a new method for in vivo imaging of gliomas and provide a clear and intuitive imaging basis for clinical diagnosis, differential diagnosis and treatment.

Sponsor

Huashan Hospital

Phase

N/A

Contacts

Yihui Guan, MD (CONTACT)

guanyihui@hotmail.com

+8613764308300

Fang Xie, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT06148207

Eligibility

Inclusion

No prior and/or current surgery, radiotherapy, or puncture biopsy (other than treatment for symptomatic relief) for brain tumors;
Platelet count \>100 x 109/L;
Urea/urea nitrogen and serum creatinine \<1.5 times upper limit of normal (ULN);
Patients diagnosed by the investigator, based on symptoms, course of disease, and MRI of the head, as having a suspected high- or low-grade brain glioma, scheduled for brain tumor resection, and with no contraindications to surgery;
1\. Patients with suspicious brain gliomas:

Exclusion

Subjects meeting any of the following criteria will be excluded from the study:
Those who cannot tolerate or are contraindicated to undergo MRI and PET;
Severe allergic reaction to any of the drugs or their components in this trial;
pregnant or lactating women or those with positive blood pregnancy test results;
Those who cannot accept or tolerate blood sample collection;